-
卵巢癌发病隐匿、不易察觉,多数病人发现时处于中晚期且伴随转移[1],导致多数病人预后不佳[2]。因此提高卵巢癌的早期诊断极为重要。但由于卵巢癌发病机制不明确,要提高早期诊断,还需从卵巢癌的发生机制入手。炎症在卵巢癌发生、发展中发挥重要作用[3]。白细胞介素(interleukin,IL)是炎性细胞因子重要组成部分,对免疫细胞成熟、增殖、分化等一系列过程具有调节作用。IL-33是IL-1的家族成员,以前体蛋白的形式存在于多种组织细胞核中,磺基转移酶(sulfotransferase,ST2)是IL-33的高亲和力受体[4]。IL-33/ST2信号通路可诱导免疫效应细胞活化,使促癌或抗癌细胞向肿瘤微环境中募集[5]。然而,IL-33在卵巢癌发生、发展的进程机制仍未清楚,是否通过ST2受体发挥作用也未明确。本研究从IL-33从发,探究IL-33/ST2对卵巢癌细胞增殖、凋亡、迁移和侵袭的影响,旨在进一步揭示卵巢癌发生、发展的分子机制,为卵巢癌的临床基础研究提供参考。
-
IL-33组、si-ST2组、IL-33+si-ST2组以及对照组的细胞存活率的比较,差异有统计学意义(P < 0.01)。其中IL-33组细胞存活率高于对照组(P < 0.01),si-ST2组细胞存活率低于对照组(P < 0.01);但IL-33+si-ST2组细胞存活率与对照组相比差异无统计学意义(P>0.05)。IL-33+si-ST2组细胞存活率显著高于si-ST2组;IL-33组细胞存活率显著高于si-ST2组(P < 0.01)(见表 1)。
分组 n OD值 对照组 3 0.75±0.08 IL-33组 3 1.36±0.04** si-ST2组 3 0.43±0.04**△△ IL-33+si-ST2组 3 0.75±0.02△△## F — 181.40 P — < 0.01 MS组内 — 0.003 q检验:与对照组比较**P < 0.01;与IL-33组比较△△P < 0.01;与si-ST2组比较##P < 0.01 表 1 不同组间细胞存活比较(x±s)
-
对照组、IL-33组、si-ST2组以及IL-33+si-ST2组流式细胞仪结果显示,在ES-2细胞中,IL-33组细胞凋亡率低于对照组;si-ST2组细胞凋亡率高于对照组和IL-33组;IL-33+si-ST2组细胞凋亡率低于si-ST2组,高于IL-33组(见图 1、表 2)。
分组 LL
(活细胞)UL
(碎片及损伤细胞)UR
(晚期凋亡)LR
(早期凋亡)凋亡率 对照组 91.62 1.72 2.44 4.23 6.67 IL-33组 94.82 1.19 1.47 2.52 3.99** si-ST2组 84.97 4.03 5.05 5.95 10.90**△△ IL-33+si-ST2组 90.47 1.59 2.80 5.14 7.90**△△## 注:与对照组比较**P < 0.01;与IL-33组比较△△P < 0.01;与si-ST2组比较##P < 0.01 表 2 ES-2凋亡数据表(%)
-
IL-33组、si-ST2组、IL-33+si-ST2组以及对照组的细胞迁移率、侵袭率的比较,差异有统计学意义(P < 0.01),其中IL-33组细胞迁移率、侵袭率均低于对照组,si-ST2组迁移、侵袭均高于对照组,IL-33+si-ST2组迁移、侵袭均高于IL-33组,低于si-ST2组,差异均有统计学意义(P < 0.01)(见图 2、图 3及表 3)。
分组 n 细胞迁移率/% 细胞侵袭率/% 对照组 3 45.83±4.15 43.06±2.64 IL-33组 3 22.88±2.36** 13.68±2.46** si-ST2组 3 73.71±3.08**△△ 66.59±1.78**△△ IL-33+si-ST2组 3 56.04±2.82**△△## 49.99±4.19**△△## F — 134.30 173.60 P — < 0.01 < 0.01 MS组内 — 10.058 8.436 q检验:与对照组比较**P < 0.01;与IL-33组比较△△P < 0.01;与si-ST2组比较##P < 0.01 表 3 不同组间细胞迁移率、侵袭率的比较(x±s)
IL-33及其受体ST2对人卵巢癌ES-2细胞增殖、凋亡、迁移和侵袭的影响
Effect of IL-33 and its receptor ST2 on the proliferation, apoptosis, migration and invasion of human ovarian cancer ES-2 cells
-
摘要:
目的探讨白细胞介素-33(IL-33)及其受体磺基转移酶(ST2)对人卵巢癌ES-2细胞增殖、凋亡、迁移和侵袭的影响。 方法采用MTT实验检测IL-33和si-ST2对ES-2人卵巢癌细胞存活率的影响;分为对照组、IL-33组、si-ST2组以及IL-33+si-ST2组,检测各组吸光度值;用流式细胞术检测IL-33和si-ST2对ES-2人卵巢癌细胞凋亡的影响,统计各组细胞凋亡数目;用细胞迁移和侵袭实验检测IL-33和si-ST2对ES-2人卵巢癌细胞迁移、侵袭的影响。 结果IL-33组、si-ST2组、IL-33+si-ST2组以及对照组的细胞存活率的比较差异有统计学意义(P < 0.01)。其中IL-33组细胞存活率高于对照组,si-ST2组细胞存活率低于对照组,IL-33+si-ST2组细胞存活率显著高于si-ST2组,IL-33组细胞存活率显著高于si-ST2组,差异均有统计学意义(P < 0.01)。IL-33组细胞凋亡率低于对照组;si-ST2组细胞凋亡率高于对照组和IL-33组;IL-33+si-ST2组细胞凋亡率低于si-ST2组,高于IL-33组。IL-33组、si-ST2组、IL-33+si-ST2组以及对照组的细胞迁移率、侵袭率的比较,差异有统计学意义(P < 0.01)。其中IL-33组细胞迁移、侵袭均低于对照组,si-ST2组迁移、侵袭均高于空白对照组,IL-33+si-ST2组迁移、侵袭均高于IL-33组,低于si-ST2组,差异均有统计学意义(P < 0.01)。 结论IL-33可促进卵巢癌ES-2细胞增殖并抑制其凋亡、迁移、侵袭;沉默ST2可抑制卵巢癌ES-2细胞增殖并促进其凋亡,使其迁移和侵袭能力下降;IL-33通过ST2途径参与影响卵巢癌ES-2细胞的增殖、凋亡、迁移和侵袭。 Abstract:ObjectiveTo investigate the effects of interleukin-33(IL-33) and its receptor sulfotransferase(ST2) on the proliferation, apoptosis, migration and invasion of human ovarian cancer ES-2 cells. MethodsThe effects of IL-33 and si-ST2 on the survival rate of ES-2 cells were detected using MTT assay, and the cells were divided into the control group, IL-33 group, si-ST2 group and IL-33+si-ST2 group.The OD value in each group was detected.The effects of IL-33 and si-ST2 on the apoptosis of ES-2 cells were detected using flow cytometry, and the number of apoptotic cells in each group was counted.The effects of IL-33 and si-ST2 on the migration and invasion of ES-2 cells were detected using the cell migration and invasion experiments. ResultsThe differences of cell survival rates among the IL-33 group, si-ST2 group, IL-33+si-ST2 and control group were statistically significant(P < 0.01).The cell survival rate in IL-33 group was higher than that in control group, the cell survival rate in si-ST2 group was lower than that in control group, the cell survival rate in IL-33+si-ST2 group was significantly higher than that in si-ST2 group, and the cell survival rate in IL-33 group was significantly higher than that in si-ST2 group(P < 0.01).The cell apoptosis rate in IL-33 group was lower than that in control group, the cell apoptosis rate in si-ST2 group was higher than that in control group and IL-33 group, and the cell apoptosis rate in IL-33+si-ST2 group was lower than that in si-ST2 group, and higher than that in IL-33 group(P < 0.01).The differences of the cell migration rate and invasion rate among the IL-33 group, si-ST2 group, IL-33+si-ST2 group and control group were statistically significant(P < 0.01).The migration and invasion rates of cells in IL-33 group were lower than those in control group, the migration and invasion rates of cells in si-ST2 group were higher than those in control group, and the migration and invasion rates of cells in IL-33+si-ST2 group were higher than those in IL-33 group, and lower than those in si-ST2 group(P < 0.01). ConclusionsIL-33 can promote the proliferation, and inhibit the apoptosis, migration and invasion of ES-2 cells.Silencing ST2 can inhibit the proliferation, and promote the apoptosis, migration and invasion of ES-2 cells.IL-33 affects the proliferation, apoptosis, migration and invasion of ES-2 cells through ST2 pathway. -
Key words:
- ovarian neoplasms /
- interleukin-33 /
- sulfotransferase /
- ES-2 cells
-
表 1 不同组间细胞存活比较(x±s)
分组 n OD值 对照组 3 0.75±0.08 IL-33组 3 1.36±0.04** si-ST2组 3 0.43±0.04**△△ IL-33+si-ST2组 3 0.75±0.02△△## F — 181.40 P — < 0.01 MS组内 — 0.003 q检验:与对照组比较**P < 0.01;与IL-33组比较△△P < 0.01;与si-ST2组比较##P < 0.01 表 2 ES-2凋亡数据表(%)
分组 LL
(活细胞)UL
(碎片及损伤细胞)UR
(晚期凋亡)LR
(早期凋亡)凋亡率 对照组 91.62 1.72 2.44 4.23 6.67 IL-33组 94.82 1.19 1.47 2.52 3.99** si-ST2组 84.97 4.03 5.05 5.95 10.90**△△ IL-33+si-ST2组 90.47 1.59 2.80 5.14 7.90**△△## 注:与对照组比较**P < 0.01;与IL-33组比较△△P < 0.01;与si-ST2组比较##P < 0.01 表 3 不同组间细胞迁移率、侵袭率的比较(x±s)
分组 n 细胞迁移率/% 细胞侵袭率/% 对照组 3 45.83±4.15 43.06±2.64 IL-33组 3 22.88±2.36** 13.68±2.46** si-ST2组 3 73.71±3.08**△△ 66.59±1.78**△△ IL-33+si-ST2组 3 56.04±2.82**△△## 49.99±4.19**△△## F — 134.30 173.60 P — < 0.01 < 0.01 MS组内 — 10.058 8.436 q检验:与对照组比较**P < 0.01;与IL-33组比较△△P < 0.01;与si-ST2组比较##P < 0.01 -
[1] 朱连成, 郭骞, 勾睿, 等.转染人附睾蛋白4基因对人卵巢癌细胞基因表达的影响[J].中国医科大学学报, 2020, 49(5):385. [2] 张维维, 张正伟, 何朗.342例卵巢癌手术患者预后影响因素分析[J].中华肿瘤防治杂志, 2019, 26(17):1288. [3] 陈丽云, 郑丽华, 罗飞, 等.炎症在卵巢癌发病中的作用研究进展[J].现代中西医结合杂志, 2015, 24(32):3646. doi: 10.3969/j.issn.1008-8849.2015.32.043 [4] 胡霞, 单晶, 孙晓滨.IL-33/ST2途径在肿瘤发生和发展中作用的研究进展[J].肿瘤预防与治疗, 2019, 32(4):366. doi: 10.3969/j.issn.1674-0904.2019.04.014 [5] LI X, LV Q, FENG Y, et al.Interleukin-33, a potential cytokine expressed in tumor microenvironment involves in antitumor immunotherapy through facilitates cd8 T cells[J].J Interferon Cytokine Res, 2018, 38(11):491. doi: 10.1089/jir.2018.0069 [6] LI L, BAI H, YANG J, et al.Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities[J].Oncotarget, 2017, 8(9):15136. doi: 10.18632/oncotarget.14767 [7] GAO X, WANG XF, YANG QT, et al.Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8+T and NK cells[J].J Immunol, 2015, 194(1):438. doi: 10.4049/jimmunol.1401344 [8] TRABERT B, PINTO L, HARTGE P, et al.Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer(PLCO)screening trial[J].Gynecol Oncol, 2014, 135(2):200. [9] 赵薇, 徐鹏, 田亚楠, 等.白介素-33在妇科肿瘤中的研究进展[J].中华全科医学, 2020, 18(3):467. [10] TONG X, BARBOUR M, HOU K, et al.Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways[J].Mol Oncol, 2016, 10(1):113. doi: 10.1016/j.molonc.2015.06.004 [11] 胡霞, 孙晓滨, 单晶.IL-33及其受体ST2在食管腺癌中的表达及其对肿瘤细胞增殖、迁移与侵袭的影响[J].四川医学, 2019, 40(1):32. [12] LI Y, SHI J, QI S, et al.IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2[J].J Exp Clin Cancer Res, 2018, 37(1):196. doi: 10.1186/s13046-018-0839-7 [13] KIM JY, LIM SC, KIM G, et al.Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity[J].Oncogene, 2015, 34(38):4928. doi: 10.1038/onc.2014.418 [14] 朱熠, 黄建鸣, 张国楠.卵巢上皮性癌MyD88表达的潜在调控机制研究进展[J].中华妇产科杂志, 2019(2):139. doi: 10.3760/cma.j.issn.0529-567x.2019.02.016 [15] YU XX, HU Z, SHEN X, et al.IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway[J].Dig Dis Sci, 2015, 60(5):1265. doi: 10.1007/s10620-014-3463-1 [16] 杨淑梅, 曹蕾, 秦天洁, 等.卵巢癌细胞中RhoA和NF-κB表达与癌细胞增殖、侵袭能力的关系[J].现代生物医学进展, 2018, 18(24):4628. [17] TONG X, BARBOUR M, HOU K, et al.Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways[J].Mol Oncol, 2016, 10(1):113. doi: 10.1016/j.molonc.2015.06.004